US Drug Recall Register
Class II · Moderate risk Terminated Initiated Feb 10, 2017 (10 years ago)

Erythromycin 2% in Cerave Cream

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility: There are also CGMP Deviations.

What was recalled

ERYTHROMYCIN 2% IN CERAVE CREAM, ERYTHROMYCIN 3% / RETINOIC ACID 0.05%, Rx only, Synergy RX, 4901 Morena Blvd # 504-A San Diego, CA 92117 (855) 792-6676

Recalling firm
Synergy Rx
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0536-2017

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Erythromycin recalls

See all
Class II · Moderate risk Ongoing

Erythromycin Tablets

Reason CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc NDC 70710-1048-3 D-0545-2026
Class II · Moderate risk Ongoing

Erythromycin Tablets

Reason CGMP Deviations; presence of N-Nitroso-Desmethyl-Erythromycin above the recommended acceptable intake limit

Zydus Pharmaceuticals (USA) Inc NDC 70710-1047-3 D-0544-2026
Class II · Moderate risk Ongoing

Erythromycin Topical Gel USP

Reason CGMP Deviations: all products within expiry are being recalled because the manufacturing firm, Teligent Pharma, Inc.is discontinuing its stability study program.

McKesson Corporation dba McKesson Drug Company NDC 63739-053-68 D-0851-2022